Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000595439 | SCV000703987 | pathogenic | not provided | 2016-11-23 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000595439 | SCV002018444 | likely pathogenic | not provided | 2019-11-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854029 | SCV002240924 | pathogenic | Fabry disease | 2022-04-12 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Fabry disease (PMID: 17532296, 18046674, 27560961, 28615118). ClinVar contains an entry for this variant (Variation ID: 498788). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects GLA function (PMID: 23935525). For these reasons, this variant has been classified as Pathogenic. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 132 of the GLA protein (p.Gly132Arg). |